211P ER-low breast cancer: Evolution from primary tumor to relapse and prognostic impactFederica Miglietta, Maria Vittoria Dieci, Rocco Cappellesso et al.|ESMO Open|2023Cited by 1
96MO Omitting anthracyclines for the adjuvant treatment of patients with triple-negative breast cancer (TNBC): A non-inferiority meta-analysisFabio Girardi, Valentina Guarneri, C. Barbieri et al.|ESMO Open|2023Cited by 0
178P PD-L1 expression in ER-low versus triple-negative (TN) advanced breast cancer (aBC), and according to phenotypic evolution from primary to recurrent diseaseFederica Miglietta, Maria Vittoria Dieci, Lorenzo Nicolè et al.|Annals of Oncology|2024Cited by 0